Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising breast cancer combo trial shutters after just one patient

NCT ID NCT05554354

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial aimed to see if adding the targeted drug binimetinib to the standard hormone therapy fulvestrant could help people with a certain genetic change (NF1) in hormone receptor-positive breast cancer that has spread. Only one person enrolled before the study was terminated, so no conclusions can be drawn about the treatment's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fulvestrant and binimetinib
What this could lead to
If it worked, this combination could offer a new targeted treatment option for people with a specific genetic change (NF1) in hormone receptor-positive metastatic breast cancer.
What could go wrong
The trial was terminated early with only one participant, so no meaningful results were obtained. It is unknown whether the combination is effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

1 person

The number who actually took part.

Started

Sep 2024

Finished

Apr 2025

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N2 based on the presence of an actionable mutation as defined in EAY191 * The patient must be enrolled on the ComboMATCH Master Registration Trial EAY191 * Note: Patients must fulfill all eligibility criteria outlined in the ComboMATCH Registration Trial EAY191 at the time of registration to EAY191-N2. This includes submission of next-generation sequencing (NGS) data from one of the National Cancer Institute (NCI) credentialed designated laboratories for all potential patients prior to treatment trial assignment. Copy number and allele frequency cutoff as per the Registration protocol * Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or, if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH registration trial (EAY191) * Please note the current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trial Support Unit (CTSU) ComboMATCH Registration protocol page * Please note novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH Registration protocol * A COMBOMATCH TREATMENT TRIAL EAY191-N2 ELIGIBILITY CRITERIA: * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information * Age \>= 18 * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Histologically or cytologically confirmed invasive breast carcinoma * Confirmed metastatic disease by either imaging or tissue diagnosis * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and one additional lesion that can be biopsied (primary, metastatic both allowed) * Patients must have inactivating or inferred inactivating NF1 alterations detected in tumor as determined by the ComboMATCH screening assessment * The tumor must have been determined to be estrogen receptor (ER) and/or progesterone receptor (PgR) positive assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone receptor testing. Patients with \>= 1% ER or PgR staining by immunohistochemistry (IHC) are considered positive * The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines * Prior use of CDK4/6 inhibitor(i) is required * Prior use of fulvestrant regardless of duration is allowed and will determine treatment assignment * Up to one line of chemotherapy in metastatic setting is allowed * Absolute neutrophil count \>= 1,500/mm\^3 * Platelet count \>= 100,000/ mm\^3 * Hemoglobin level \>= 10 g/dL * Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula * Total bilirubin level =\< institutional upper limit of normal * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =\< 5.0 x ULN * For patients who will be assigned to Cohort 2 (fulvestrant-resistant), a left ventricular ejection fraction (LVEF) assessment must be performed within 12 weeks prior to registration. The LVEF must be \>= 50% regardless of the cardiac imaging facility's lower limit of normal. (LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted based on institutional/situational preferences) * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial * ELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO COHORT 2: Cohort migration: Patients treated with control treatment fulvestrant who experience disease progression may be eligible to migrate to Cohort 2 and receive combination treatment with binimetinib and fulvestrant. Patients who choose to do so must meet laboratory values and performance status requirements below and should begin treatment within 28 days * PATIENTS WHO MIGRATE TO COHORT 2: Patient's willingness to migrate to Cohort 2 affirmed * PATIENTS WHO MIGRATE TO COHORT 2: The patient must have an ECOG performance status of 0-2 * PATIENTS WHO MIGRATE TO COHORT 2: Absolute neutrophil count \>= 1,500/mm\^3 * PATIENTS WHO MIGRATE TO COHORT 2: Platelet count \>= 100,000/ mm\^3 * PATIENTS WHO MIGRATE TO COHORT 2: Hemoglobin level \>= 10 g/dL * PATIENTS WHO MIGRATE TO COHORT 2: Total bilirubin level =\< institutional upper limit of normal (ULN) * PATIENTS WHO MIGRATE TO COHORT 2: AST and ALT must be =\< 5.0 x ULN * PATIENTS WHO MIGRATE TO COHORT 2: Creatinine clearance (CrCL) of ≥30 mL/min by the Cockcroft-Gault formula * PATIENTS WHO MIGRATE TO COHORT 2: A LVEF performed within the last 3 months must be \>= 50% regardless of the cardiac imaging facility's lower limit of normal (LVEF assessment performed by echocardiogram is preferred; however, MUGA scan may be substituted based on institutional/situational preferences) * PATIENTS WHO MIGRATE TO COHORT 2: Pregnancy test according to institutional standards must be negative (for patients of childbearing potential only) Exclusion Criteria: * Concurrent anticancer therapy * Active autoimmune disease requiring systemic treatment within the past 3 months, documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents * Active brain metastasis. Brain metastases that have been stable for at least 1 month after completion of treatment are not an exclusion criterion * History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous, chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration * Patients will be excluded if they currently have the following risk factors for RVO that are documented prior to the enrollment: * Known uncontrolled glaucoma with intra-ocular pressures \>= 21 mmHg * Known serum cholesterol \>= grade 2. * Known hypertriglyceridemia \>= grade 2 * Known hyperglycemia (fasting) \>= grade 2 * Patients with baseline QT corrected for heart rate (QTc) \> 500 ms, either induced by medication or congenital long QT syndrome will be excluded due to known side effects of binimetinib * Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) \>= grade 2 * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications * Other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results * Pregnancy or lactation at the time of registration or intention to become pregnant during the study (Note: Pregnancy testing according to institutional standards for patients of childbearing potential) * For binimetinib, highly effective contraception should be used for at least 30 days after the last dose, and patients should not breastfeed for 3 days after the last dose * For fulvestrant, highly effective contraception should be used for 1 year after the last dose, and patients should not breastfeed for 1 year after the last dose * Use of any investigational product within 30 days prior to study entry * INELIGIBILITY CRITERIA FOR COHORT 1, TREATMENT REGIMEN 2 PATIENTS WHO MIGRATE TO COHORT 2 * PATIENTS WHO MIGRATE TO COHORT 2: Not a candidate for binimetinib in the opinion of the treating investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anatomic stage IV breast cancer ajcc V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer Her2-receptor negative breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anatomic stage IV breast cancer ajcc V8 Metastatic HER2-negative breast carcinoma Metastatic hormone receptor-positive breast carcinoma

Contacts and locations

Locations

  • AMG Crystal Lake - Oncology

    Crystal Lake, Illinois, 60014, United States

  • AMG Libertyville - Oncology

    Libertyville, Illinois, 60048, United States

  • Abbott-Northwestern Hospital

    Minneapolis, Minnesota, 55407, United States

  • Adena Regional Medical Center

    Chillicothe, Ohio, 45601, United States

  • Advocate Christ Medical Center

    Oak Lawn, Illinois, 60453-2699, United States

  • Advocate Good Shepherd Hospital

    Barrington, Illinois, 60010, United States

  • Advocate Illinois Masonic Medical Center

    Chicago, Illinois, 60657, United States

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois, 60068, United States

  • Advocate Sherman Hospital

    Elgin, Illinois, 60123, United States

  • Advocate South Suburban Hospital

    Hazel Crest, Illinois, 60429, United States

  • Asplundh Cancer Pavilion

    Willow Grove, Pennsylvania, 19090, United States

  • Atrium Medical Center-Middletown Regional Hospital

    Franklin, Ohio, 45005-1066, United States

  • Aultman Health Foundation

    Canton, Ohio, 44710, United States

  • Aurora Bay Area Medical Group-Marinette

    Marinette, Wisconsin, 54143, United States

  • Aurora BayCare Medical Center

    Green Bay, Wisconsin, 54311, United States

  • Aurora Cancer Care-Grafton

    Grafton, Wisconsin, 53024, United States

  • Aurora Cancer Care-Kenosha South

    Kenosha, Wisconsin, 53142, United States

  • Aurora Cancer Care-Milwaukee

    Milwaukee, Wisconsin, 53209, United States

  • Aurora Cancer Care-Milwaukee West

    Wauwatosa, Wisconsin, 53226, United States

  • Aurora Cancer Care-Racine

    Racine, Wisconsin, 53406, United States

  • Aurora Cancer Care-Southern Lakes VLCC

    Burlington, Wisconsin, 53105, United States

  • Aurora Health Care Germantown Health Center

    Germantown, Wisconsin, 53022, United States

  • Aurora Medical Center in Summit

    Summit, Wisconsin, 53066, United States

  • Aurora Saint Luke's Medical Center

    Milwaukee, Wisconsin, 53215, United States

  • Aurora Saint Luke's South Shore

    Cudahy, Wisconsin, 53110, United States

  • Aurora Sinai Medical Center

    Milwaukee, Wisconsin, 53233, United States

  • Aurora West Allis Medical Center

    West Allis, Wisconsin, 53227, United States

  • Benefis Sletten Cancer Institute

    Great Falls, Montana, 59405, United States

  • Billings Clinic Cancer Center

    Billings, Montana, 59101, United States

  • Bozeman Health Deaconess Hospital

    Bozeman, Montana, 59715, United States

  • Bryn Mawr Hospital

    Bryn Mawr, Pennsylvania, 19010, United States

  • Cancer Hematology Centers - Flint

    Flint, Michigan, 48503, United States

  • Carle Cancer Center

    Urbana, Illinois, 61801, United States

  • Carle Physician Group-Effingham

    Effingham, Illinois, 62401, United States

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois, 61938, United States

  • Carle at The Riverfront

    Danville, Illinois, 61832, United States

  • Centro Comprensivo de Cancer de UPR

    San Juan, 00927, Puerto Rico

  • Chelsea Hospital

    Chelsea, Michigan, 48118, United States

  • Community Hospital of Anaconda

    Anaconda, Montana, 59711, United States

  • Community Medical Center

    Missoula, Montana, 59804, United States

  • Condell Memorial Hospital

    Libertyville, Illinois, 60048, United States

  • Contra Costa Regional Medical Center

    Martinez, California, 94553-3156, United States

  • Corewell Health Beaumont Troy Hospital

    Troy, Michigan, 48085, United States

  • Corewell Health Dearborn Hospital

    Dearborn, Michigan, 48124, United States

  • Corewell Health Farmington Hills Hospital

    Farmington Hills, Michigan, 48336, United States

  • Corewell Health William Beaumont University Hospital

    Royal Oak, Michigan, 48073, United States

  • Dayton Physician LLC - Englewood

    Dayton, Ohio, 45415, United States

  • Doctors Cancer Center

    Manati, 00674, Puerto Rico

  • Duluth Clinic Ashland

    Ashland, Wisconsin, 54806, United States

  • Epic Care Cyberknife Center

    Walnut Creek, California, 94597, United States

  • Epic Care Partners in Cancer Care

    Emeryville, California, 94608, United States

  • Epic Care-Dublin

    Dublin, California, 94568, United States

  • Essentia Health - Deer River Clinic

    Deer River, Minnesota, 56636, United States

  • Essentia Health Cancer Center

    Duluth, Minnesota, 55805, United States

  • Essentia Health Hibbing Clinic

    Hibbing, Minnesota, 55746, United States

  • Essentia Health Sandstone

    Sandstone, Minnesota, 55072, United States

  • Essentia Health Virginia Clinic

    Virginia, Minnesota, 55792, United States

  • Fairfield Medical Center

    Lancaster, Ohio, 43130, United States

  • Fairview Southdale Hospital

    Edina, Minnesota, 55435, United States

  • Genesee Hematology Oncology PC

    Flint, Michigan, 48503, United States

  • Genesis Healthcare System Cancer Care Center

    Zanesville, Ohio, 43701, United States

  • Genesys Hurley Cancer Institute

    Flint, Michigan, 48503, United States

  • Gulfport Memorial Hospital

    Gulfport, Mississippi, 39502, United States

  • Gundersen Lutheran Medical Center

    La Crosse, Wisconsin, 54601, United States

  • Henry Ford Saint John Hospital - Macomb Medical

    Macomb, Michigan, 48044, United States

  • Hurley Medical Center

    Flint, Michigan, 48503, United States

  • Huron Gastroenterology PC

    Ypsilanti, Michigan, 48106, United States

  • John H Stroger Jr Hospital of Cook County

    Chicago, Illinois, 60612, United States

  • Kettering Medical Center

    Kettering, Ohio, 45429, United States

  • Kingman Regional Medical Center

    Kingman, Arizona, 86401, United States

  • Knox Community Hospital

    Mount Vernon, Ohio, 43050, United States

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho, 83854, United States

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho, 83864, United States

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho, 83814, United States

  • Lafayette Family Cancer Center-EMMC

    Brewer, Maine, 04412, United States

  • Lankenau Medical Center

    Wynnewood, Pennsylvania, 19096, United States

  • Licking Memorial Hospital

    Newark, Ohio, 43055, United States

  • Logan Health Medical Center

    Kalispell, Montana, 59901, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Marietta Memorial Hospital

    Marietta, Ohio, 45750, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Memorial Hospital

    Marysville, Ohio, 43040, United States

  • Memorial Hospital East

    Shiloh, Illinois, 62269, United States

  • Mercy Health - Perrysburg Hospital

    Perrysburg, Ohio, 43551, United States

  • Mercy Health - Saint Anne Hospital

    Toledo, Ohio, 43623, United States

  • Mercy Hospital

    Coon Rapids, Minnesota, 55433, United States

  • Mercy Medical Center - Des Moines

    Des Moines, Iowa, 50314, United States

  • Miami Valley Cancer Care and Infusion

    Greenville, Ohio, 45331, United States

  • Miami Valley Hospital

    Dayton, Ohio, 45409, United States

  • Miami Valley Hospital North

    Dayton, Ohio, 45415, United States

  • Miami Valley Hospital South

    Centerville, Ohio, 45459, United States

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York, 10461, United States

  • Mount Carmel East Hospital

    Columbus, Ohio, 43213, United States

  • MyMichigan Medical Center Saginaw

    Saginaw, Michigan, 48601, United States

  • MyMichigan Medical Center Tawas

    Tawas City, Michigan, 48764, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

    Yakima, Washington, 98902, United States

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois, 60134, United States

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois, 60115, United States

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois, 60555, United States

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois, 60045, United States

  • Northwestern Medicine Orland Park

    Orland Park, Illinois, 60462, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Oncology Hematology Associates of Saginaw Valley PC

    Saginaw, Michigan, 48604, United States

  • OptumCare Cancer Care at Charleston

    Las Vegas, Nevada, 89102, United States

  • OptumCare Cancer Care at Fort Apache

    Las Vegas, Nevada, 89148, United States

  • OptumCare Cancer Care at Seven Hills

    Henderson, Nevada, 89052, United States

  • PCR Oncology

    Arroyo Grande, California, 93420, United States

  • PROncology

    San Juan, 00927, Puerto Rico

  • Paoli Memorial Hospital

    Paoli, Pennsylvania, 19301, United States

  • Park Nicollet Clinic - Saint Louis Park

    Saint Louis Park, Minnesota, 55416, United States

  • Premier Blood and Cancer Center

    Dayton, Ohio, 45409, United States

  • Providence Newberg Medical Center

    Newberg, Oregon, 97132, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Providence Saint Vincent Medical Center

    Portland, Oregon, 97225, United States

  • Providence Willamette Falls Medical Center

    Oregon City, Oregon, 97045, United States

  • Puerto Rico Hematology Oncology Group

    Bayamón, 00961, Puerto Rico

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Riddle Memorial Hospital

    Media, Pennsylvania, 19063, United States

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho, 83706, United States

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho, 83605, United States

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho, 83687, United States

  • Saint Alphonsus Cancer Care Center-Ontario

    Ontario, Oregon, 97914, United States

  • Saint Ann's Hospital

    Westerville, Ohio, 43081, United States

  • Saint John's Cancer Institute

    Santa Monica, California, 90404, United States

  • Saint John's Hospital - Healtheast

    Maplewood, Minnesota, 55109, United States

  • Saint Joseph Hospital - Orange

    Orange, California, 92868, United States

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho, 83712, United States

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho, 83619, United States

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho, 83642, United States

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho, 83687, United States

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho, 83301, United States

  • Saint Mary's Oncology/Hematology Associates of West Branch

    West Branch, Michigan, 48661, United States

  • Sanford Bismarck Medical Center

    Bismarck, North Dakota, 58501, United States

  • Sanford Broadway Medical Center

    Fargo, North Dakota, 58122, United States

  • Sanford Cancer Center Oncology Clinic

    Sioux Falls, South Dakota, 57104, United States

  • Sanford Joe Lueken Cancer Center

    Bemidji, Minnesota, 56601, United States

  • Sanford Roger Maris Cancer Center

    Fargo, North Dakota, 58122, United States

  • Sanford USD Medical Center - Sioux Falls

    Sioux Falls, South Dakota, 57117-5134, United States

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri, 63136, United States

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri, 63376, United States

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri, 63141, United States

  • Siteman Cancer Center-South County

    St Louis, Missouri, 63129, United States

  • Southern Ohio Medical Center

    Portsmouth, Ohio, 45662, United States

  • Springfield Regional Cancer Center

    Springfield, Ohio, 45504, United States

  • Springfield Regional Medical Center

    Springfield, Ohio, 45504, United States

  • Strecker Cancer Center-Belpre

    Belpre, Ohio, 45714, United States

  • Swedish Cancer Institute-Edmonds

    Edmonds, Washington, 98026, United States

  • Swedish Cancer Institute-Issaquah

    Issaquah, Washington, 98029, United States

  • The Mark H Zangmeister Center

    Columbus, Ohio, 43219, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton

    Brighton, Michigan, 48114, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Canton

    Canton, Michigan, 48188, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

    Chelsea, Michigan, 48118, United States

  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

    Ypsilanti, Michigan, 48197, United States

  • Trinity Health Medical Center - Brighton

    Brighton, Michigan, 48114, United States

  • Trinity Health Medical Center - Canton

    Canton, Michigan, 48188, United States

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor

    Ann Arbor, Michigan, 48106, United States

  • Trinity Health Saint Mary Mercy Livonia Hospital

    Livonia, Michigan, 48154, United States

  • Tufts Medical Center

    Boston, Massachusetts, 02111, United States

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa, 50023, United States

  • UI Health Care Mission Cancer and Blood - Des Moines Clinic

    Des Moines, Iowa, 50309, United States

  • UM Sylvester Comprehensive Cancer Center at Aventura

    Aventura, Florida, 33180, United States

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida, 33146, United States

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida, 33442, United States

  • UM Sylvester Comprehensive Cancer Center at Kendall

    Miami, Florida, 33176, United States

  • UM Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida, 33324, United States

  • UPMC Altoona

    Altoona, Pennsylvania, 16601, United States

  • UPMC Cancer Centers - Arnold Palmer Pavilion

    Greensburg, Pennsylvania, 15601, United States

  • UPMC Hillman Cancer Center - Monroeville

    Monroeville, Pennsylvania, 15146, United States

  • UPMC Hillman Cancer Center Erie

    Erie, Pennsylvania, 16505, United States

  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

    Mechanicsburg, Pennsylvania, 17050, United States

  • UPMC Western Maryland

    Cumberland, Maryland, 21502, United States

  • UPMC-Passavant Hospital

    Pittsburgh, Pennsylvania, 15237, United States

  • United Hospital

    Saint Paul, Minnesota, 55102, United States

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, 35233, United States

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky, 40536, United States

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland, 21201, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, 33136, United States

  • University of Michigan Health - Sparrow Lansing

    Lansing, Michigan, 48912, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin, 53718, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, 53792, United States

  • Upper Valley Medical Center

    Troy, Ohio, 45373, United States

  • VCU Community Memorial Health Center

    South Hill, Virginia, 23970, United States

  • VCU Massey Cancer Center at Stony Point

    Richmond, Virginia, 23235, United States

  • Valley Medical Center

    Renton, Washington, 98055, United States

  • Vince Lombardi Cancer Clinic - Oshkosh

    Oshkosh, Wisconsin, 54904, United States

  • Vince Lombardi Cancer Clinic-Sheboygan

    Sheboygan, Wisconsin, 53081, United States

  • Vince Lombardi Cancer Clinic-Two Rivers

    Two Rivers, Wisconsin, 54241, United States

  • Virginia Cancer Institute

    Richmond, Virginia, 23229, United States

  • Virginia Commonwealth University/Massey Cancer Center

    Richmond, Virginia, 23298, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.